Genentech is one of the world's largest biotechnology companies as measured by its $88 billion market capitalization, slightly behind that of biotech rival Amgen.

It has built its recent success on blockbuster cancer drugs, including Rituxan for non-Hodgkin's lymphoma and Avastin for colon cancer. Read more.

The new program will be the first doctorate-level program offered by Louisville-based Sullivan University, which has several master's degree programs in addition to associate's and bachelor's degree programs.

Faulkner Real Estate, which will continue to develop Class A office space and commercial retail centers, already owns a significant medical office portfolio in Louisville that it manages and leases for Norton.

A laboratory rat unable to use its right front paw because of a spinal cord injury struggles to walk across a rope, loses its footing and falls.

Then a rat that had the same injury scurries across the rope without a problem, just weeks after an injection containing adult stem cells from a human nose that were transformed into nerve cells.

The rats are part of a line of groundbreaking research at the University of Louisville that could lead to treatments for spinal cord injuries, multiple sclerosis, Parkinson's disease and other nerve disorders.

The rat's improvement after the injection is the second major discovery in the past few months at UofL that promises progress without using embryonic stem cells.

In December, a research team at the James Graham Brown Cancer Center announced it had transformed stem cells from adult mice into brain, heart, nerve and pancreatic cells.

The nasal stem-cell research - published most recently last week in the journal "Stem Cells" - involves using certain chemicals to direct the cells to become neurons, which send and receive messages between the nervous system and other parts of the body. Read more.

The company, which will have about 1,700 employees in Louisville following its hiring spree, also is adding office space in Louisville and moving some of its employees to accommodate the growth.

The Micro Lending Program, which will be administered by the Louisville Metro Development Authority, will offer primary financing for new companies with loans of $10,000 to $30,000.

AML would construct a 100,000-square-foot facility on the now-vacant site.

The planned building would have a truck-loading area in the rear of the facility and 26- to 30-foot ceilings.

After extensive delays, the partners planning the $25 million, 82-condominium project called Fleur-de-lis across from Louisville Slugger Field are proceeding with the development.

The Louisville Metro Council introduced a measure declaring as surplus the 1.1-acre site on the southwest corner of Main and Preston streets and authorizing its sale to the developers. The city acquired the land in the mid-1990s in the deal that led to the ballpark's construction.

The units will have 1,000 to 2,100 square feet of space. Interiors will be built to suit buyers, with hardwood floors, marble countertops, bay windows overlooking the street and patios. About 20,000 square feet of first-level commercial space is planned, half of which probably will go to a restaurant.

The first units should be ready for occupancy by the middle of next year. Read more.

Developers John Hollenbach and Greg Oakley are seeking permission to build a 283-acre business park near Jeffersontown.

The developers have agreed to spend an estimated $7 to $8 million to install a four-mile sewer main, bringing sewers to a 4.6-square-mile area and opening up the whole area for development. Read more.